Table 1.
1. Pulmonary arterial hypertension (PAH) | 1.1. Idiopathic | |
1.2. Heritable | 1.2.1. BMPR2 | |
1.2.2. ALK1, ENG, SMAD9, CAV1, KCNK3 | ||
1.2.3. Unknown | ||
1.3. Drug and toxin induced | ||
1.4. Associated with the following: | 1.4.1. Connective tissue diseases | |
1.4.2. Human immunodeficiency virus (HIV) infection | ||
1.4.3. Portal hypertension | ||
1.4.4. Congenital heart diseases | ||
1.4.5. Schistosomiasis | ||
1′. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH) | 1′.1. Idiopathic | |
1′.2. Heritable | 1′.2.1. EIF2AK4 mutation | |
1′.2.2. Other mutations | ||
1′.3. Drug, toxin, and radiation induced | ||
1′.4. Connective tissue diseases | ||
1′.5. Human immunodeficiency virus (HIV) infection | ||
1″. Persistent pulmonary hypertension of the newborn (PPHN) | ||
2. Pulmonary hypertension due to left heart disease | 2.1. Left ventricular systolic dysfunction | |
2.2. Left ventricular diastolic dysfunction | ||
2.3. Valvular disease | ||
2.4. Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies | ||
3. Pulmonary hypertension due to lung disease and/or hypoxia | 3.1. Chronic obstructive pulmonary disease | |
3.2. Interstitial lung disease | ||
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern | ||
3.4. Sleep-disordered breathing | ||
3.5. Alveolar hypoventilation disorders | ||
3.6. Chronic exposure to high altitude | ||
3.7. Developmental abnormalities | ||
4. Chronic thromboembolic pulmonary hypertension (CTEPH) | ||
5. Pulmonary hypertension with unclear multifactorial mechanisms | 5.1. Hematologic disorders: chronic haemolytic anaemia, myeloproliferative disorders, splenectomy | |
5.2. Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis (LAM) | ||
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders | ||
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis, segmental PH |
BMPR2 = bone morphogenetic protein receptor type 2; EIF2AK4 = eukaryotic translation initiation factor 2 alpha kinase 4.